Nu Skin sell-off creates buying opportunity, says Wedbush Wedbush believes that the sell-off in Nu Skin's stock yesterday based on a critical article in China Daily "appears highly unwarranted." The firm finds the newspaper's allegations similar to those made by short sellers about two years ago. Wedbush thinks the company's fundamental momentum has been accelerating and it keeps a $143 price target and Outperform rating on the shares.
News For NUS From The Last 14 Days
Check below for free stories on NUS the last two weeks.